IMMUNOVANT, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
IMMUNOVANT, INC. (IMVT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$5.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$5.00K, a 101.80% decline year-over-year.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$467.00K.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$253.00K, a 144.46% decline year-over-year.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$287.00K, a 418.89% decline year-over-year.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2026 was -$729.00K.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$449.00K, a 142.52% decline from fiscal 2024.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $1.06M, a 135.71% increase from fiscal 2023.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $448.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.00K 10-Q · filed 2026-08-06 | -$472.00K derived: sum of 2 quarters · filed 2026-08-06 | -$725.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$720.00K derived: sum of 2 quarters · filed 2026-05-20 | -$1.01M derived: sum of 3 quarters · filed 2026-05-20 | -$729.00K 10-K · filed 2026-05-20 |
| 2025-12-31 | -$253.00K 10-Q · filed 2026-02-06 | -$540.00K derived: sum of 2 quarters · filed 2026-02-06 | -$262.00K 10-Q · filed 2026-02-06 | -$1.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | -$287.00K 10-Q · filed 2025-11-10 | -$9.00K 10-Q · filed 2025-11-10 | -$1.03M derived: sum of 3 quarters · filed 2026-08-06 | -$460.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $278.00K 10-Q · filed 2026-08-06 | -$742.00K derived: sum of 2 quarters · filed 2026-08-06 | -$173.00K derived: sum of 3 quarters · filed 2026-08-06 | -$83.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$451.00K derived: sum of 2 quarters · filed 2026-05-20 | -$361.00K derived: sum of 3 quarters · filed 2026-05-20 | -$449.00K 10-K · filed 2026-05-20 |
| 2024-12-31 | $569.00K 10-Q · filed 2026-02-06 | $659.00K derived: sum of 2 quarters · filed 2026-02-06 | $571.00K 10-Q · filed 2026-02-06 | $3.08M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $90.00K 10-Q · filed 2025-11-10 | $2.00K 10-Q · filed 2025-11-10 | $2.51M derived: sum of 3 quarters · filed 2026-05-20 | $1.40M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$88.00K 10-Q · filed 2025-08-11 | $2.42M derived: sum of 2 quarters · filed 2026-05-20 | $1.31M derived: sum of 3 quarters · filed 2026-05-20 | $1.38M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $1.40M derived: sum of 2 quarters · filed 2026-05-20 | $1.46M derived: sum of 3 quarters · filed 2026-05-20 | $1.06M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$1.11M 10-Q · filed 2025-02-06 | -$1.04M derived: sum of 2 quarters · filed 2025-02-06 | -$1.45M 10-Q · filed 2025-02-06 | |
| 2023-09-30 | $69.00K 10-Q · filed 2024-11-07 | $339.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $270.00K 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $448.00K 10-K · filed 2025-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |